How the 340B Program’s Structural Incentives Distort Healthcare Markets: A Case Study in Policy Feedback Loops
Original framing: “Opinion: How CMS plans to fix a major flaw in the 340B drug discount program” — STAT News
Pharmacists in 340B hospitals report feeling complicit in a system where they’re pressured to ‘meet diversion quotas’ to justify their institution’s discount eligibility. Patients in federally qualified health centers (FQHCs) describe being turned away when 340B drugs run out, as hospitals prioritize high-margin resales. Meanwhile, rural clinics in Appalachia and the Mississippi Delta—disproportionately Black and Indigenous—have seen their 340B funds siphoned to urban hospital chains, leaving them with crumbling infrastructure. These voices are systematically excluded from policy debates, treated as passive beneficiaries rather than stakeholders.
The 340B program’s crisis is not a failure of implementation but a symptom of a healthcare economy designed to extract value from vulnerability.
Its expansion was driven by a coalition of hospital chains, pharmaceutical lobbyists, and policymakers who treated equity as a market opportunity rather than a public good—a dynamic that mirrors the broader history of U.S. healthcare, from the Hill-Burton Act to the Affordable Care Act’s exchanges. The CMS proposal to cap drug purchases per patient is a *trickster* fix: it addresses the symptom (diversion) without dismantling the system that rewards it. Solutions must move beyond technical adjustments to restructure power—decoupling subsidies from institutions, centering marginalized voices in oversight, and adopting cross-cultural models that prioritize health over revenue. The path forward lies in treating drugs as a public resource, not a commodity to be gamed by those who claim to steward it.